Article    Table of Contents                    Full Text of this article    PDF of this article (PDFs free after 6 months)    Summary for Patients    Figures/Tables List    Related articles in Annals  Services    Send comment/rapid response letter    Notify a friend about this article    Alert me when this article is cited    Add to Personal Archive    Download to Citation Manager    ACP Search                            Get Permissions  Google Scholar    Search for Related Content  PubMed Articles in PubMed by Author:    Forman, L. M.    Diamond, R. H.    Related Articles in PubMed    PubMed Citation    PubMed

BRIEF COMMUNICATION

Hepatic Failure in a Patient Taking Rosiglitazone

Lisa M. Forman, MD; David A. Simmons, MD; and Robert H. Diamond, MD

18 January 2000 | Volume 132 Issue 2 | Pages 118-121

Background: Rosiglitazone maleate is the second approved oral hypoglycemic agent of the thiazolidinedione class. The first, troglitazone, has been associated with liver failure, occasionally resulting in liver transplantation or death. There have been no reports to date of rosiglitazone-associated elevations in the alanine aminotransferase level or hepatotoxicity.

Objective: To report the clinical characteristics of liver failure developing in a patient receiving rosiglitazone.

Design: Case report.

Setting: University hospital.

Patient: 69-year-old man taking rosiglitazone, 4 mg/d.

Intervention: Discontinuation of rosiglitazone therapy and treatment with lactulose, vitamin K, fresh frozen plasma, ventilatory assistance, and intensive care unit support.

Measurements: Blood test monitoring, including toxicology screening, liver function tests, coagulation studies, serum chemistries, and complete blood counts.

Results: After 21 days of rosiglitazone therapy, hepatic failure developed. Other causes of hepatic failure, such as viruses and toxins, were excluded, although it is possible that congestive heart failure was also a causative factor. The patient recovered fully with supportive care.

Conclusion: Rosiglitazone may be associated with hepatic failure.

Author and Article Information

From the Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.

Requests for Reprints: Robert H. Diamond, MD, Division of Gastroenterology, Hospital of the University of Pennsylvania, 600 CRB, 415 Curie Boulevard, Philadelphia, PA, 19104. For reprint orders in quantities exceeding 100, please contact the Reprints Coordinator; phone, 215-351-2657; e-mail, reprints{at}mail.acponline.org.

Current Author Addresses: Dr. Forman: Division of Gastroenterology, Hospital of the University of Pennsylvania, 34th and Spruce Streets, Philadelphia, PA 19104.

Dr. Simmons: Division of Endocrinology, Diabetes, and Metabolism, Hospital of the University of Pennsylvania, 34th and Spruce Streets, Philadelphia, PA 19104.

Dr. Diamond: Division of Gastroenterology, Hospital of the University of Pennsylvania, 600 CRB, 415 Curie Boulevard, Philadelphia, PA 19104.

Author Contributions: Conception and design: L.M. Forman, R.H. Diamond.

Analysis and interpretation of the data: L.M. Forman, D.A. Simmons, R.H. Diamond.

Drafting of the article: L.M. Forman, D.A. Simmons, R.H. Diamond.

Critical revision of the article for important intellectual content: L.M. Forman, D.A. Simmons, R.H. Diamond.

Final approval of the article: L.M. Forman, D.A. Simmons, R.H. Diamond.

Provision of study materials or patients: D.A. Simmons, R.H. Diamond.

Administrative, technical, or logistic support: R.H. Diamond.

Collection and assembly of data: L.M. Forman, R.H. Diamond.

Related articles in Annals:

Summaries for Patients
Liver Damage in a Person Taking the Diabetes Drug Rosiglitazone

Annals 2000 132: 118. [Full Text]  

Brief Communications
Hepatocellular Injury in a Patient Receiving Rosiglitazone: A Case Report
Jameela Al-Salman, Heider Arjomand, David G. Kemp, AND Manoj Mittal

Annals 2000 132: 121-124. [ABSTRACT][SUMMARY][Full Text]  

Letters
Rosiglitazone and Hepatic Failure
Jeffrey Freid, Daniel Everitt, AND Jerome Boscia

Annals 2000 132: 164. [Full Text]  

Letters
Rosiglitazone and Liver Failure
William L. Isley AND Julie C. Oki

Annals 2000 133: 393. [Full Text]  

Letters
Rosiglitazone and Liver Failure
Lisa M. Forman AND Robert H. Diamond

Annals 2000 133: 393-394. [Full Text]  

Letters
Rosiglitazone Toxicity
Ravi Sudhir Ravinuthala AND Uday Nori

Annals 2000 133: 658. [Full Text]  

Letters
Isolated Elevation of Alkaline Phosphatase Level Associated with Rosiglitazone
David M. Hachey, Michael P. O'Neil, AND Rex W. Force

Annals 2000 133: 752. [Full Text]  

Letters
Hepatocellular Injury in a Patient Receiving Pioglitazone
Kenji Maeda

Annals 2001 135: 306. [Full Text]  

Letters
Did This Drug Cause My Patient's Hepatitis?
Neil Kaplowitz, James H. Lewis, AND Paul B. Watkins

Annals 2003 138: 159. [Full Text]  

This article has been cited by other articles:

				M. H. El-Naggar, A. Helmy, M. Moawad, M. Al-Omary, Y. Al-Kadhi, and B. Habib Late-Onset Rosiglitazone-Associated Acute Liver Failure in a Patient with Hodgkin's Lymphoma Ann. Pharmacother., May 1, 2008; 42(5): 713 - 718. [Abstract] [Full Text] [PDF]

				K. G. Tolman, V. Fonseca, A. Dalpiaz, and M. H. Tan Spectrum of Liver Disease in Type 2 Diabetes and Management of Patients With Diabetes and Liver Disease Diabetes Care, March 1, 2007; 30(3): 734 - 743. [Full Text] [PDF]

				H. A. Spiller and T. S. Sawyer Toxicology of oral antidiabetic medications Am. J. Health Syst. Pharm., May 15, 2006; 63(10): 929 - 938. [Abstract] [Full Text] [PDF]

				M. A. Peraza, A. D. Burdick, H. E. Marin, F. J. Gonzalez, and J. M. Peters The Toxicology of Ligands for Peroxisome Proliferator-Activated Receptors (PPAR) Toxicol. Sci., April 1, 2006; 90(2): 269 - 295. [Abstract] [Full Text] [PDF]

				K. G. Tolman, V. Fonseca, M. H. Tan, and A. Dalpiaz Narrative Review: Hepatobiliary Disease in Type 2 Diabetes Mellitus Ann Intern Med, December 21, 2004; 141(12): 946 - 956. [Abstract] [Full Text] [PDF]

				T. R Marcy, M. L Britton, and S. M Blevins Second-Generation Thiazolidinediones and Hepatotoxicity Ann. Pharmacother., September 1, 2004; 38(9): 1419 - 1423. [Abstract] [Full Text] [PDF]

				W. M. Lee Drug-Induced Hepatotoxicity N. Engl. J. Med., July 31, 2003; 349(5): 474 - 485. [Full Text] [PDF]

				J. Sahi, C. B. Black, G. A. Hamilton, X. Zheng, S. Jolley, K. A. Rose, D. Gilbert, E. L. LeCluyse, and M. W. Sinz Comparative Effects of Thiazolidinediones on in Vitro P450 Enzyme Induction and Inhibition Drug Metab. Dispos., April 1, 2003; 31(4): 439 - 446. [Abstract] [Full Text] [PDF]

				N. Kaplowitz, J. H. Lewis, and P. B. Watkins Did This Drug Cause My Patient's Hepatitis? Ann Intern Med, January 21, 2003; 138(2): 159 - 159. [Full Text] [PDF]

				R. K. Campbell and J. White Counseling Patients With Type 2 Diabetes and Insulin Resistance in the Outpatient Setting The Diabetes Educator, November 1, 2002; 28(6): 938 - 957. [PDF]

				J. A. Kiayias, E. D. Vlachou, E. Theodosopoulou, and E. Lakka-Papadodima Rosiglitazone in Combination With Glimepiride Plus Metformin in Type 2 Diabetic Patients Diabetes Care, July 1, 2002; 25(7): 1251 - 1252. [Full Text] [PDF]

				H. E. Lebovitz, M. Kreider, and M. I. Freed Evaluation of Liver Function in Type 2 Diabetic Patients During Clinical Trials: Evidence that rosiglitazone does not cause hepatic dysfunction Diabetes Care, May 1, 2002; 25(5): 815 - 821. [Abstract] [Full Text] [PDF]

				L. D. May, J. H. Lefkowitch, M. T. Kram, and D. E. Rubin Mixed Hepatocellular-Cholestatic Liver Injury after Pioglitazone Therapy Ann Intern Med, March 19, 2002; 136(6): 449 - 452. [Abstract] [Full Text] [PDF]

				D. W. Nierenberg "Did This Drug Cause My Patient's Hepatitis?" and Related Questions Ann Intern Med, March 19, 2002; 136(6): 480 - 483. [Full Text] [PDF]

				K. Maeda Hepatocellular Injury in a Patient Receiving Pioglitazone Ann Intern Med, August 21, 2001; 135(4): 306 - 306. [Full Text] [PDF]

				A. A. Parulkar, M. L. Pendergrass, R. Granda-Ayala, T. R. Lee, and V. A. Fonseca Nonhypoglycemic Effects of Thiazolidinediones Ann Intern Med, January 2, 2001; 134(1): 61 - 71. [Abstract] [Full Text] [PDF]

				M. J. Lenhard and W. B. Funk Failure to Develop Hepatic Injury From Rosiglitazone in a Patient With a History of Troglitazone-Induced Hepatitis Diabetes Care, January 1, 2001; 24(1): 168 - 169. [Full Text]

				D. M. Hachey, M. P. O'Neil, and R. W. Force Isolated Elevation of Alkaline Phosphatase Level Associated with Rosiglitazone Ann Intern Med, November 7, 2000; 133(9): 752 - 752. [Full Text] [PDF]

				R. S. Ravinuthala and U. Nori Rosiglitazone Toxicity Ann Intern Med, October 17, 2000; 133(8): 658 - 658. [Full Text] [PDF]

				W. L. Isley and J. C. Oki Rosiglitazone and Liver Failure Ann Intern Med, September 5, 2000; 133(5): 393 - 393. [Full Text] [PDF]

				S. Campbell Management of Type 2 Diabetes in the Geriatric Patient Journal of Pharmacy Practice, August 1, 2000; 13(4): 263 - 276. [Abstract] [PDF]

				Is Rosiglitazone Hepatotoxic, Too? Journal Watch Gastroenterology, April 1, 2000; 2000(401): 18 - 18. [Full Text]

				Is Rosiglitazone Hepatotoxic, Too? Journal Watch (General), February 1, 2000; 2000(201): 1 - 1. [Full Text]

				J. Freid, D. Everitt, and J. Boscia Rosiglitazone and Hepatic Failure Ann Intern Med, January 18, 2000; 132(2): 164 - 164. [Full Text] [PDF]